The composite primary efficacy endpoint was percentage of patients whose haematological variables and organ volumes remained stable for @ months ( ie , haemoglobin decrease not more than @ g/L , platelet count decrease not more than @ % , spleen volume increase not more than @ % , and liver volume increase not more than @ % , in multiples of normal from baseline ) .